Varenicline: The Newest Agent for Smoking Cessation

Lisa A. Potts; Candice L. Garwood


Am J Health Syst Pharm. 2007;64(13):1381-1384. 

In This Article


Varenicline, a newly approved agent for smoking cessation, offers a new option to patients who cannot tolerate the adverse effects associated with NRT and bupropion. It is also an alternative to consider in patients with contraindications to such therapies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.